Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex Faspro
daratumumab + hyaluronidase-fihj · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with high-risk smoldering multiple myeloma.
LAMPGEN ANALYSIS
Why it matters
The approval introduces an intervention intended to delay progression in a high-risk precursor population before active myeloma develops.
What research teams should watch
Apply explicit high-risk criteria, exclude active myeloma, and balance monitoring visits against burden for asymptomatic participants.
PRIMARY RECORDS